Abbott Laboratories Point of Care revenue
Point of Care revenue at Abbott Laboratories came to $158.0M for the quarter to 31 Dec 2025, up 7.5% from a year earlier.
As Abbott Laboratories reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 20 Feb 2026.
By quarter
| Period ending | Point of Care revenue | Change on a year | Filed |
|---|---|---|---|
| 31 Dec 2025 | $158.0M | up 7.5% | 20 Feb 2026 |
| 30 Sep 2025 | $158.0M | up 8.2% | 29 Oct 2025 |
| 30 Jun 2025 | $148.0M | down 5.1% | 30 Jul 2025 |
| 31 Mar 2025 | $142.0M | up 2.2% | 30 Apr 2025 |
| 31 Dec 2024 | $147.0M | down 1.3% | 21 Feb 2025 |
| 30 Sep 2024 | $146.0M | up 4.3% | 31 Oct 2024 |
| 30 Jun 2024 | $156.0M | up 9.9% | 31 Jul 2024 |
| 31 Mar 2024 | $139.0M | up 3.7% | 2 May 2024 |
| 31 Dec 2023 | $149.0M | — | 16 Feb 2024 |
| 30 Sep 2023 | $140.0M | — | 1 Nov 2023 |
| 30 Jun 2023 | $142.0M | — | 3 Aug 2023 |
| 31 Mar 2023 | $134.0M | — | 4 May 2023 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Abbott Laboratories: Diabetes Care revenue · Core Laboratory revenue · Adult Nutritionals revenue · Key Emerging Markets revenue · Pediatric Nutritionals revenue · Cancer Diagnostics revenue · Rapid and Molecular revenue · Electrophysiology revenue · Vascular revenue · Rhythm Management revenue · Rapid Diagnostics revenue · Structural Heart revenue · Heart Failure revenue · Neuromodulation revenue · Molecular revenue · COVID-19 Testing revenue · Medical Devices revenue · Diagnostic Products revenue · Nutritional Products revenue · Established Pharmaceuticals revenue · financial statements
Every KPI and segment of ABT, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
